Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Glioblastoma Clinical Trial

— SC9/ABX  

Official title:

Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04528680
• Other study ID #: NU 20C03
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 29, 2020
• Est. completion date: September 2025

Study information

• Verified date: November 2023
• Source: Northwestern University
• Contact: Christina Amidei, APN, PhD
• Phone: (312) 695-9124
• Email: christina.amidei[@]nm.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial we will implant a novel device with 9 ultrasound emitters allowing to temporarily and reversibly open the BBB immediately prior to chemotherapy infusion with albumin-bound paclitaxel.

In the phase 1 component, increasing doses of chemotherapy will be delivered as long deemed safe based on the prior patient not experiencing severe toxicity. Once the the recommended dosing has been established, carboplatin will be added to the regimen and additional patients will be treated in order to better evaluate the antitumor efficacy of this novel treatment.

The device will be implanted at the time of surgical resection of the recurrent tumor. During that procedure and when feasible, a first test dose of the chemotherapy will be administered in the operating room after sonication (procedure of activating ultrasound and opening the BBB) and tissue concentrations in different parts of the resected tumor will be measured. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered.

The objectives of this trial are to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the BBB increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.

Description:

Eligible patients will undergo craniotomy for tumor resection. During the tumor resection and when possible, an initial low dose of albumin-bound paclitaxel will be given following sonication. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The sonication device will be implanted at the end of the procedure. In phase 1, about two weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel administration with MRI to quantify extent of blood brain barrier opening. Sonication and administration of albumin-bound paclitaxel will continue every 3 weeks until disease progression. The planned albumin-bound paclitaxel starting dose is 40 mg/m2, to be escalated in the absence of significant toxicity up to 260 mg/m2. Blood samples for circulating tumor DNA will also be collected before and after each sonication. In phase 2, pre-sonication carboplatin at AUC 5 will be added to the regimen, with a safety run-in for the first 6 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 57
• Est. completion date: September 2025
• Est. primary completion date: September 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Confirmed diagnosis of Isocitrate Dehydrogenase 1 (IDH1) wild-type glioblastoma on pathology from initial surgery (e.g. IDH R132H neg); morphologic or molecular determination of grade 4

2. Ability to undergo contrast-enhanced MRI

3. Radiographic evidence of tumor recurrence/progression after failure of 1 - 2 lines of prior therapy

4. Measurable or evaluable disease

1. Measurable: contrast-enhancement (bidirectional diameters = 1cm) on MRI

2. Non-measurable/evaluable: contrast-enhancement diameters < 1 cm

5. Maximal tumor diameter pre-surgery = 70 mm on T1wMRI

6. Candidate for at least partial surgical resection

7. Greater 12 weeks from completion of radiation therapy

8. Age = 18 years

9. If receiving dexamethasone for mass effect, a stable daily dose of dexamethasone at < 6 mg within 7 days of registration, or if dexamethasone dose is decreasing, average daily dose of < 6 mg in the 7 days prior to registration. Patients on dexamethasone for reasons other than mass effect may still be enrolled.

10. WHO performance status = 2 (equivalent to Karnofsky Performance Status (KPS) of =70)

11. Adequate hepatic, renal and bone marrow function, documented with normal laboratory values or no more than grade 1 outside the norm performed within 14 days prior to registration

12. For patients with a childbearing potential

1. Negative pregnancy test within 14 days prior to registration

2. Agreement to use adequate contraception for the duration of study participation, and for 3 and 6 months after the last dose of albumin-bound paclitaxel for men and women of childbearing potential, respectively.

13. Have the ability to understand and the willingness to sign a written informed consent prior to registration on study

14. Be willing and able to comply with the protocol for the duration of the study

15. Provide written, signed and dated informed consent prior to study registration. NOTE:

no study-specific screening procedures may be performed until written consent has been obtained

Exclusion Criteria:

1. Have multifocal disease that cannot be encompassed in the ultrasound fields:

1. e.g. > 70-mm apart

2. tumor located in the posterior fossa

2. Patients at risk of cranial wound dehiscence

3. Have uncontrolled epilepsy or require treatment with enzyme-inducing antiepileptics

4. Have clinical evidence of peripheral neuropathy on examination

5. Have received any other investigational agents within 4 weeks of registration

6. Have received prior therapy with or have history of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel or carboplatin

7. Medical contraindications to Abraxane® or carboplatin

8. Have an uncontrolled intercurrent illness

9. Are pregnant or nursing

10. Have a history of active malignancy within 3 years prior to registration.

11. Have a known history of hypersensitivity reactions to perflutren lipid microsphere components or to any of the inactive ingredients in Definity® (the FDA-approved ultrasound contrast agent to be used in this study)

12. Patients with coils, clips, shunts, intravascular stents, and/or non-removable wafer, non resorbable dura substitute, or reservoirs.

13. Patients with medical need to continue antiplatelet therapy.

14. Patients with known significant cardiac disease, known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg), uncontrolled systemic hypertension, or adult respiratory distress syndrome (patient at risk for microbubble reaction).

15. Patients with impaired thermo-regulation or temperature sensation (due to device)

Related Conditions & MeSH terms

• GBM
• Glioblastoma
• Glioblastoma Multiforme
• Glioblastoma, IDH-wildtype
• Gliosarcoma
• Recurrence
• Recurrent Glioblastoma

Intervention

Device:
• Sonication for opening of blood-brain barrier
Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles

Drug:
• Chemotherapy, albumin-bound paclitaxel
Intravenous infusion of ABX over 30 minutes
• Chemotherapy, carboplatin
Intravenous infusion of carboplatin over 30 minutes

Locations

Country	Name	City	State
United States	Northwestern Memorial Hospital	Chicago	Illinois

Sponsors (4)

Lead Sponsor	Collaborator
Northwestern University	Bristol-Myers Squibb, CarThera, Lantheus Medical Imaging

Country where clinical trial is conducted

United States, 

References & Publications (3)

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, Andre A, Lafon C, Chapelon JY, Delattre JY, Carpentier A. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19. — View Citation

Sonabend AM, Stupp R. Overcoming the Blood-Brain Barrier with an Implantable Ultrasound Device. Clin Cancer Res. 2019 Jul 1;25(13):3750-3752. doi: 10.1158/1078-0432.CCR-19-0932. Epub 2019 May 10. — View Citation

Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C, Carpentier A, Desseaux C, Canney M, Muzzio M, Stupp R, Sonabend AM. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clin Cancer Res. 2020 Jan 15;26(2):477-486. doi: 10.1158/1078-0432.CCR-19-2182. Epub 2019 Dec 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Extent of tumor and peritumoral tissue covered by BBB opening	increase in Gd contrast enhancement post sonication	1st cycle (cycle = 3 weeks)
Other	Objective response rate (RANO)	measurement of tumor shrinkage (if there is residual disease)	6 months
Other	Measurement of circulating tumor DNA, methods and units for this measure are to be determined and still under evaluation.	compare before and after sonication	1st cycle, cycles 2 - 6 as applicable (cycle = 3 weeks)
Primary	Dose limiting toxicity (Phase1)	Occurrence of = grade 3 treatment related toxicity	1st treatment cycle = 3 weeks
Primary	1-year survival rate (Phase 2)	Survival time from date of tumor resection and device implantation	12-months
Primary	Relationship between overall survival and SSR3 (Phase 2)	Survival time from date of tumor resection and device implantation	through study completion, an average of 2 years
Secondary	Incidence of side effects/toxicity associated with Sonication/ABX treatment	Safety and tolerance	12 months